SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-009335
Filing Date
2021-05-06
Accepted
2021-05-06 16:37:27
Documents
62
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20210331.htm   iXBRL 10-Q 1135935
2 EX-10.1 exhibit101.htm EX-10.1 70601
3 EX-10.2 exhibit102.htm EX-10.2 72130
4 EX-31.1 mrtx03312021ex311.htm EX-31.1 14519
5 EX-31.2 mrtx03312021ex312.htm EX-31.2 14304
6 EX-32.1 mrtx03312021ex321.htm EX-32.1 8216
  Complete submission text file 0001628280-21-009335.txt   4910761

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20210331.xsd EX-101.SCH 35144
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20210331_cal.xml EX-101.CAL 60946
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20210331_def.xml EX-101.DEF 131758
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20210331_lab.xml EX-101.LAB 406660
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20210331_pre.xml EX-101.PRE 244838
12 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20210331_htm.xml XML 737321
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 21898477
SIC: 2834 Pharmaceutical Preparations